Company Overview


About PW Medtech Group Limited (1358.HK)


    PW Medtech Group Limited is a leading medical device company in China, focusing on high growth and high-margin segments of China’s medical device industry. Its two principal businesses include research and development, production and distribution of regenerative medical biomaterials and advanced infusion sets products. The Group was founded by Chairman Ms. Yue’e Zhang (Ms. Zhang is also an early founder of Lepu Medical Technology (Beijing) Co., Ltd., a company listed on the Shenzhen Stock Exchange (stock code: 300003).) and successfully listed on the Main Board of the Hong Kong Stock Exchange on 8 November, 2013. With the Group’s outstanding growth and profitability, as well as its excellent acquisition and integration capability, the Group was named as “the future Medtronic in China” and “industry consolidator” in the capital market after its listing, and ranked 30th on Forbes’ “2015 China’s Listed Potential Enterprise Top 100”.

 

    Since 10 March 2014, PW Medtech Group Limited has been selected as a constituent of Hang Seng Composite Index Series, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index-Consumer Goods, Hang Seng Global Composite Index, Hang Seng Mainland Consumer Goods Index and Hang Seng Broad Consumption Index.

 

    At present, the two core business segments of PW Medtech Group are regenerative medical biomaterials segment, which principally involves the manufacturing of dura mater, and advanced infusion sets segment, which principally involves the manufacturing of precision filter infusion sets and non-PVC infusion sets. PW Medtech Group Limited has developed into the domestic giant of these two segments and owns several high-tech subsidiaries.

 

    As for the Regenerative Medical Biomaterial Business, PW Medtech is currently the largest artificial dura mater manufacturer in China. As an essential medical material for craniotomy operations, artificial dura mater is very crucial for the recovery of patient after the operation and directly affects the result of craniotomy operation, therefore, the requirements on artificial dura mater are particularly strict both in terms of safety and efficiency. PW Medtech Group’s artificial dura mater brand “Tian Yi Fu (天义福)” has ranked as the top market share in China for years, which is a strong testament of the recognition and faith of numerous Class III hospitals and outstanding practitioners gained by our track record of good curative effect and high safety level. The Group also upgrades technology and develops new products continuously as it considers innovation as a key to success. PW Medtech has widened the application of regenerative medical biomaterials to the fields of oral and maxillofacial surgery and orthopedic and will continue to explore other medical applications.

 

    Leveraging on the extensive experience and leading technology of PW Medtech Group in medical biomaterials, the Group penetrated into the cosmetic industry in 2016, introducing its new product — medical cosmetic grade mask under the brand of “LE SEUL (諾頌)”. Concerning about the threat to consumers’ skin health posed by a wide range of different quality of skin care products in the market, the Group leverages its experience on manufacturing and quality control in the medical biomaterials industry to produce skin care products that can be trusted by consumers with rigorous attitude. Due to the Group’s insistence on “quality and safety come first” as a player of the medical industry, in terms of quality, “LE SEUL” mask product is more superior to 95% of similar products currently available in the domestic market.

 

    Another important segment of the Group is the advanced infusion sets segment. Throughout the years, the “Fert” brand under the Group has been focusing on providing a safer and more efficient solution for infusion therapy. Fert Technology is the first domestic enterprise engaging in the research and development as well as manufacturing of precision filter infusion sets since 1990s and has participated in formulating the national standard of precision filter infusion sets products. As a leading enterprise in the field of infusion healthcare, Fert Technology has opened a new chapter in China’s development of safe infusion. These precision filter infusion sets can substantially mitigate the impact of insoluble particles in medical solution on patients during the process of infusion, thereby largely reduces the risk of complication. At the beginning of this century, Fert Technology is also one of the first three manufacturers in China which pioneered the use of non-PVC safe material to produce infusion sets. Such products can effectively replace traditional PVC infusion sets and avoid the potential adverse impact on patients caused by some harmful materials in traditional infusion sets. The rising awareness of the medical industry on the safety issue of infusion in recent years has particularly demonstrated the farsightedness of PW Medtech as a pioneering manufacturer of advanced infusion sets. The Group has maintained the second largest market share in the domestic advanced infusion sets market and ranked number one in Beijing market for years. In the future, PW Medtech will continue to place high importance on the field of infusion therapy and introduce new healthcare products such as disposable intravenous cannula to contribute to the safety and efficiency of medical healthcare industry.

 

    Apart from continue to focus on organic growth derived from its core business segments, the Group will also leverage on the synergy effect among research and development, distribution network and business operation through its outstanding acquisition and integration strategy. The Group aims to become a comprehensive platform for high-value medical consumables in China.

 

    Through years of effort, PW Medtech has not only established an extensive distribution network covering 31 provinces, cities and municipalities across China, but also built up a strong research and development team as well as a professional, mature and well-established management team with each key person-in-charge having years of working and management experience in their respective fields. Building on the platform of existing businesses, PW Medtech will continue to explore and innovate. By adhering to the ideology of focusing on medical care and revering life, the Group will make its best effort to contribute to China’s medical industry. Our people hold the belief that only integrity can create our prestigious brands, only innovation can make the market leader, only professionalism can provide intimate care for health.




Subsidiaries

Beijing Fert Technology Co., Ltd.

Founded in 2001,Beijing Fert Technology Co., Ltd is the first high-tech enterprise to apply the state-of-the-art nuclear physics technology to infusion set products. Its business includes research and development, production and sales of a variety of  advanced  infusion sets,including the precision filter products sets,non-PVC infusion sets, light resistance infusion set and  etc.

Beijing TianXinFu Medical Appliance Co., Ltd.

Beijing TianXinFu Medical Appliance Co., Ltd. Beijing TianXinFu Medical Appliance Co., Ltd is a high- technology enterprise company integrating research, development, production and sales service together. The main products are implantable medical devices (type III), classified into two medical areas - regenerative medical biomaterials and orthopedics.

Xuzhou Yijia Medical Appliance Co., Ltd.

Xuzhou Yijia Medical Appliance Co. is focus on the manufacturing of advance infusion sets and their components.